Clin2
NCT06601517Likely a fitNot yet recruiting

Study of drug interactions with HDM1002 in healthy and overweight adults

Healthy Adult SubjectOverweight Subject

Treatments studied

Part of Hormones & metabolism clinical trials.

This trial tests how a new medicine, HDM1002, interacts with four common drugs (repaglinide, atorvastatin, digoxin, rosuvastatin) in healthy and overweight adults. The results will help guide safe dosing for future patients.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
30 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You are generally healthy based on medical history, blood tests, vital signs, heart tracing (ECG), and physical exam.
  • You are between 18 and 45 years old.
  • If male, you weigh at least 110 pounds (50 kg); if female, at least 99 pounds (45 kg).
  • Your body mass index (BMI) is between 19 and 30 kg/m2.
  • You have no personal or family history of medullary thyroid cancer, thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2.
  • You have no history of chronic pancreatitis or recent pancreatitis, gallbladder inflammation, or surgery affecting stomach emptying or drug absorption.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07331389Recruiting· Phase 1
How HDM1002 interacts with common drugs and diabetes medications

This study tests how a new drug called HDM1002 interacts with common diabetes medications (metformin, empagliflozin) and other drugs like warfarin and valsartan. If you are a generally healthy adult (age 18-45) with a higher BMI, this trial helps ensure the new drug is safe when taken with other medicines.

Hefei
NCT06562088Not yet recruiting· Phase 1
Study of HDM1002 drug interactions in healthy volunteers

This study tests how a new drug (HDM1002) interacts with two other common medicines—rifampin and itraconazole—in healthy volunteers. The results will help doctors understand how to safely use the drug with other medications.

Hefei, Anhui
NCT06608329Not yet recruiting· Phase 1
Study of HDM1002: How it works with and without food

This study looks at how the drug HDM1002 is absorbed by the body, both when taken with food and on an empty stomach. It helps researchers understand the best way to take the medication.

Hangzhou, Zhejiang
NCT06576401Recruiting· Phase 1
HDM1002 metabolism study in healthy Chinese men

This study tests how a new drug called HDM1002 leaves the body, using a tiny amount of a radioactive marker. It's for healthy men, and the results will help researchers understand how the drug works.

Suzhou, Jiangsu
NCT07594847Recruiting· Phase 1
Safety study of HDM1002 tablets on heart rhythm in healthy adults

This study tests whether a new experimental medication called HDM1002 affects how your heart beats in a healthy population. Researchers want to make sure the drug is safe before testing it in patients with actual medical conditions.

Zibo, Shangdong
NCT07394114Recruiting· Phase 3
Study of a new medicine for type 2 diabetes not controlled by diet and exercise

This trial tests a new medicine called HDM1005 for people with type 2 diabetes who haven't been helped enough by diet and exercise alone, and who haven't taken any diabetes medication in the last 12 weeks. It aims to see if the medicine can help lower blood sugar levels safely.

Beijing

Hear when a new Healthy Adult Subject trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.